$2.09
1.65% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US14757U1097
Symbol
CASI
Sector
Industry

CASI Pharmaceuticals Inc Stock price

$2.09
-0.19 8.33% 1M
-3.44 62.21% 6M
-0.74 26.15% YTD
-1.22 36.86% 1Y
-5.05 70.72% 3Y
-17.31 89.23% 5Y
-12.01 85.18% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.04 1.65%
ISIN
US14757U1097
Symbol
CASI
Sector
Industry

Key metrics

Market capitalization $28.48m
Enterprise Value $34.53m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 1.21
P/S ratio (TTM) P/S ratio 1.00
P/B ratio (TTM) P/B ratio 17.79
Revenue growth (TTM) Revenue growth -13.78%
Revenue (TTM) Revenue $28.54m
EBIT (operating result TTM) EBIT $-39.21m
Cash position $16.09m
EPS (TTM) EPS $-2.70
P/E forward negative
P/S forward 1.87
EV/Sales forward 2.00
Short interest 0.69%
Show more

Is CASI Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

CASI Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast CASI Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast CASI Pharmaceuticals Inc:

Buy
100%

Financial data from CASI Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
29 29
14% 14%
100%
- Direct Costs 17 17
31% 31%
61%
11 11
44% 44%
39%
- Selling and Administrative Expenses 41 41
10% 10%
145%
- Research and Development Expense 8.92 8.92
58% 58%
31%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -39 -39
22% 22%
-137%
Net Profit -39 -39
49% 49%
-138%

In millions USD.

Don't miss a Thing! We will send you all news about CASI Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CASI Pharmaceuticals Inc Stock News

Neutral
Accesswire
one day ago
BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (th...
Neutral
Accesswire
4 days ago
BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, and provided an update on key highlight...
Neutral
Accesswire
3 months ago
BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocyto...
More CASI Pharmaceuticals Inc News

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Head office United States
CEO Wei He
Employees 233
Founded 1991
Website www.casipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today